Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Fig. 2

Representative microphotographs of liver sections stained with hematoxylin eosin and NAFLD activity score (NAS) in the five groups. Original magnification ×200. Data are mean ± SE. ¶P < 0.001 vs. vehicle; **P < 0.01, ††P < 0.001 vs. Linagliptin alone

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us